ImmunoPrecise Antibodies Ltd (NASDAQ:IPA) has a beta value of 0.21 and has seen 0.41 million shares traded in the recent trading session. The company, currently valued at $12.90M, closed the recent trade at $0.41 per share which meant it gained $0.01 on the day or 2.16% during that session. The IPA stock price is -534.15% off its 52-week high price of $2.60 and 21.95% above the 52-week low of $0.32. If we look at the company’s 10-day average daily trading volume, we find that it stood at 0.31 million shares traded. The 3-month trading volume is 565.17K shares.
ImmunoPrecise Antibodies Ltd (NASDAQ:IPA) trade information
Sporting 2.16% in the green today, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the IPA stock price touched $0.41 or saw a rise of 8.89%. Year-to-date, ImmunoPrecise Antibodies Ltd shares have moved -75.91%, while the 5-day performance has seen it change -1.81%. Over the past 30 days, the shares of ImmunoPrecise Antibodies Ltd (NASDAQ:IPA) have changed -10.42%. Short interest in the company has seen 0.69 million shares shorted with days to cover at 0.7.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
ImmunoPrecise Antibodies Ltd (IPA) estimates and forecasts
Figures show that ImmunoPrecise Antibodies Ltd shares have outperformed across the wider relevant industry. The company’s shares have lost -60.57% over the past 6 months, with this year growth rate of 65.38%, compared to 24.90% for the industry. Revenue growth from the last financial year stood is estimated to be 0.92%.
2 analysts offering their estimates for the company have set an average revenue estimate of 6.58M for the current quarter. 2 have an estimated revenue figure of 6.77M for the next ending quarter. Year-ago sales stood 6.22M and 6.46M respectively for this quarter and the next, and analysts expect sales will grow by 5.85% for the current quarter and 0.92% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -11.23% over the past 5 years.
IPA Dividends
ImmunoPrecise Antibodies Ltd is expected to release its next earnings report in January this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
ImmunoPrecise Antibodies Ltd (NASDAQ:IPA)’s Major holders
Insiders own 12.06% of the company shares, while shares held by institutions stand at 6.58% with a share float percentage of 7.48%. Investors are also buoyed by the number of investors in a company, with ImmunoPrecise Antibodies Ltd having a total of 20.0 institutions that hold shares in the company. The top two institutional holders are INGALLS & SNYDER LLC with over 1.3 million shares worth more than $1.31 million. As of 2024-06-30, INGALLS & SNYDER LLC held 5.0209% of shares outstanding.
The other major institutional holder is RENAISSANCE TECHNOLOGIES LLC, with the holding of over 63910.0 shares as of 2024-06-30. The firm’s total holdings are worth over $64549.0 and represent 0.2477% of shares outstanding.
